Cellebrite DI (NASDAQ:CLBT) Shares Up 9.8% – Here’s Why

Posted by Brenda Bartman on May 29th, 2026

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report)’s share price traded up 9.8% during trading on Friday . The company traded as high as $14.43 and last traded at $14.4990. 1,505,539 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 1,917,233 shares. The stock had previously closed at $13.20.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Needham & Company LLC cut their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson began coverage on Cellebrite DI in a research report on Wednesday. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.40.

View Our Latest Analysis on Cellebrite DI

Cellebrite DI Stock Up 9.8%

The stock has a 50-day simple moving average of $13.26 and a two-hundred day simple moving average of $15.30. The firm has a market cap of $3.62 billion, a PE ratio of 51.77, a P/E/G ratio of 1.52 and a beta of 1.15.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 13,269 shares of company stock worth $169,592 over the last quarter. 5.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its stake in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Cellebrite DI during the third quarter valued at about $40,000. CWM LLC grew its stake in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the last quarter. First Horizon Corp grew its stake in shares of Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after buying an additional 2,337 shares during the last quarter. Finally, Vestcor Inc bought a new position in shares of Cellebrite DI during the third quarter valued at about $70,000. 45.88% of the stock is owned by institutional investors.

About Cellebrite DI

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.